Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05488548 · ClinicalTrials.gov registry record · Phase 1
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
A Phase 1 study of Chronic Myelomonocytic Leukemia and Myelofibrosis, sponsored by Epigenetix.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
- 6
- Study locations
NCT05488548 is a Phase 1 study of Chronic Myelomonocytic Leukemia and Myelofibrosis that is actively recruiting participants, run by Epigenetix. The registered enrollment target is 75 participants, below the 88-participant average among 73 other Chronic Myelomonocytic Leukemia trials with a reported enrollment target (15% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT05488548, a Phase 1 study of Chronic Myelomonocytic Leukemia and Myelofibrosis, is actively recruiting participants, sponsored by Epigenetix.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
- 6
- Study locations
Study Summary
A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies
Conditions Studied
Interventions
- DRUG EP31670
Study Locations (6)
Arizona
- Mayo Clinic Arizona - Phoenix
Florida
- Mayo Clinic Florida - Jacksonville
Massachusetts
- Dana Farber Cancer Institute - Boston
Minnesota
- Mayo Clinic Rochester - Rochester
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Washington
- University of Washington/Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2022-12-21 |
| Est. Completion | 2025-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05488548
The ClinicalTrials.gov registry entry for NCT05488548 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 88-participant average among 73 other Chronic Myelomonocytic Leukemia trials with a reported enrollment target (15% lower). The listed sponsor is Epigenetix, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Chronic Myelomonocytic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which EP31670 is the first listed.
NCT05488548 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Arizona, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05488548 about?
NCT05488548 is a clinical study titled "Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies". A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies
What is the current status of trial NCT05488548?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2022-12-21. Estimated completion is 2025-05.
What conditions does trial NCT05488548 study?
This clinical trial studies the following conditions: Chronic Myelomonocytic Leukemia, Myelofibrosis, Castrate Resistant Prostate Cancer, NUT Carcinoma.
What interventions are being tested in trial NCT05488548?
The interventions under investigation include: EP31670 (DRUG).
Who is sponsoring clinical trial NCT05488548?
This trial is sponsored by Epigenetix, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05488548 being conducted?
This trial has 6 study locations across Arizona, Florida, Massachusetts, Minnesota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Myelomonocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
RECRUITING · Phase 1
-
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
RECRUITING · Phase 1
-
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.
RECRUITING · Phase 1
-
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.